Skip to main content
SpringerLink
Log in

Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Riluzole is the only drug shown to slow the course of amyotrophic lateral sclerosis (ALS). Patients with ALS-associated dysphagia may have to discontinue riluzole therapy because of their inability to swallow the tablet formulation of the drug. An oral suspension of riluzole (Teglutik®) has recently been approved, which may allow patients with ALS-associated dysphagia to continue riluzole therapy for longer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Calvo AC, Manzano R, Mendonca DM, et al. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int. 2014;2014:925101.

    PubMed  PubMed Central  Google Scholar 

  2. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75.

    Article  PubMed  Google Scholar 

  3. Orsini M, Oliveira AB, Nascimento OJ, et al. Amyotrophic lateral sclerosis: new perpectives and update. Neurol Int. 2015;7(2):5885.

    PubMed  PubMed Central  Google Scholar 

  4. Goyal NA, Mozaffar T. Respiratory and nutritional support in amyotrophic lateral sclerosis. Curr Treat Options Neurol. 2014;16(2):270.

    Article  PubMed  Google Scholar 

  5. Kühnlein P, Gdynia H-J, Sperfeld A-D, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7):366–74.

    Article  PubMed  Google Scholar 

  6. Muscaritoli M, Kushta I, Molfino A, et al. Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition. 2012;28(10):959–66.

    Article  PubMed  Google Scholar 

  7. Higo R, Tayama N, Nito T. Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Auris Nasus Larynx. 2004;31(3):247–54.

    Article  PubMed  Google Scholar 

  8. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430(1–2):197–206.

    Article  CAS  PubMed  Google Scholar 

  9. Wright D, Chapman N, Foundling-Miah M, et al. Consensus guideline on the medication management of adults with swallowing difficulties. 2006. http://www.swallowingdifficulties.com/images/pdf/dysphagia%20full%20guideline2.pdf. Accessed 18 May 2016.

  10. Covis Pharmaceuticals Inc. Rilutek (riluzole) tablets for oral use: US prescribing information. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020599s017lbl.pdf. Accessed 18 May 2016.

  11. National Health Service. NEEMMC guidelines for tablet crushing and administration via enteral feeding tubes. 2013. http://www.colchesterhospital.nhs.uk/formulary/NEEMMC%20Guidelines%20for%20Tablet%20Crushing.pdf. Accessed 18 May 2016.

  12. Kurien M, McAlindon ME, Westaby D, et al. Percutaneous endoscopic gastrostomy (PEG) feeding. BMJ. 2010;340:c2414.

    Article  PubMed  Google Scholar 

  13. British Pharmaceutical Nutrition Group. Drug administration via enteral feeding tubes. http://www.bapen.org.uk/pdfs/d_and_e/de_gp_guide.pdf. Accessed 18 May 2016.

  14. Martindale Pharmaceuticals Ltd. Teglutik 5 mg/mL oral suspension: UK summary of product characteristics. 2015. https://www.medicines.org.uk/emc/medicine/31219. Accessed 17 Feb 2016.

  15. Martindale Pharma. Martindale Pharma® announces first oral liquid form of riluzole, Teglutik®, launched in the UK [media release]. 2015. http://www.martidalepharma.co.uk. Accessed 18 Feb 2016.

  16. European Patent Office. Global patent index: EP 2405890 A2. 2016. http://data.epo.org/gpi/EP2405890A2-RILUZOLE-AQUEOUS-SUSPENSIONS. Accessed 18 May 2016.

  17. Cheramy A, Barbeito L, Godeheu G, et al. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett. 1992;147(2):209–12.

    Article  CAS  PubMed  Google Scholar 

  18. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol. 1993;250(3):473–6.

    Article  CAS  PubMed  Google Scholar 

  19. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147–57.

    Article  CAS  PubMed  Google Scholar 

  20. European Medicines Agency. Rilutek (riluzole) film-coated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000109/WC500056586.pdf. Accessed 18 May 2016.

  21. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425–31.

    Article  CAS  PubMed  Google Scholar 

  22. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585–91.

    Article  CAS  PubMed  Google Scholar 

  23. Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609–15.

    Article  CAS  PubMed  Google Scholar 

  24. Yanagisawa N, Tashiro K, Tohgi H, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo controlled study in Japan. Igakuno Ayumi. 1997;182:851–66.

    Google Scholar 

  25. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.

  26. Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis: a population-based study in Ireland, 1996-2000. J Neurol. 2003;250(4):473–9.

    Article  CAS  PubMed  Google Scholar 

  27. Mitchell JD, O’Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler. 2006;7(2):67–71.

    Article  PubMed  Google Scholar 

  28. Turner MR, Bakker M, Sham P, et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):15–21.

    Article  CAS  PubMed  Google Scholar 

  29. Georgoulopoulou E, Fini N, Vinceti M, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5–6):338–45.

    Article  PubMed  Google Scholar 

  30. Lacomblez L, Bensimon G, Leigh PN, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):23–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The review was reviewed by: A.C. Calvo, University of Zaragoza, Zaragoza, Spain; P. Couratier, CHU de Limoges, Limoges, France; G. Laekeman, Katholieke Universiteit Leuven, Leuven, Belgium; F. Viader, CHU de Caen, Caen, France. During the peer review process, the manufacturer of riluzole oral suspension was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

GM. Keating is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M. Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Ther Perspect 32, 282–286 (2016). https://doi.org/10.1007/s40267-016-0312-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0312-7

Keywords

Search

Navigation